Leaders from Cigna, CVS, Humana, OptumRx and Prime Therapeutics have agreed to appear at the April 3 hearing.
Committee Chairman Chuck Grassley, R-Iowa, and ranking member Ron Wyden, D-Ore., invited the executives this month.
“Middlemen in the healthcare industry owe patients and taxpayers an explanation of their role. There’s far too much bureaucracy and too little transparency getting in the way of affordable, quality health care,” Mr. Grassley and Mr. Wyden told The Hill.
The committee’s hearing will be the third on drug-pricing this year. In February, seven pharmaceutical executives testified before Congress.
More articles on pharmacy:
Harvard gets $100M infusion for drug research from hedge fund
Purdue Pharma CEO: Bankruptcy is ‘an option’ amid lawsuits
Intermountain CEO Dr. Marc Harrison: How Civica Rx will disrupt the drug industry
